nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclizine—SULT1E1—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0681	0.129	CbGpPWpGaD
Cyclizine—SULT1E1—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.0602	0.114	CbGpPWpGaD
Cyclizine—SULT1E1—prostate gland—urinary bladder cancer	0.0377	0.266	CbGeAlD
Cyclizine—SULT1E1—Estrogen metabolism—NQO1—urinary bladder cancer	0.0263	0.0499	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTZ1—urinary bladder cancer	0.0221	0.0419	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTO2—urinary bladder cancer	0.0209	0.0397	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—NAT1—urinary bladder cancer	0.0209	0.0397	CbGpPWpGaD
Cyclizine—SULT1E1—female reproductive system—urinary bladder cancer	0.0206	0.145	CbGeAlD
Cyclizine—SULT1E1—Estrogen metabolism—GSTM1—urinary bladder cancer	0.0202	0.0382	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—UGT2B7—urinary bladder cancer	0.0191	0.0363	CbGpPWpGaD
Cyclizine—CYP2C9—urine—urinary bladder cancer	0.019	0.134	CbGeAlD
Cyclizine—SULT1E1—vagina—urinary bladder cancer	0.0186	0.131	CbGeAlD
Cyclizine—SULT1E1—Biological oxidations—GSTZ1—urinary bladder cancer	0.0129	0.0245	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.0127	0.0242	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTO2—urinary bladder cancer	0.0122	0.0232	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—NAT1—urinary bladder cancer	0.0122	0.0232	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.0121	0.0229	CbGpPWpGaD
Cyclizine—SULT1E1—lymph node—urinary bladder cancer	0.012	0.0849	CbGeAlD
Cyclizine—SULT1E1—Phase II conjugation—NAT2—urinary bladder cancer	0.0115	0.0217	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—UGT2B7—urinary bladder cancer	0.0112	0.0212	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.011	0.0209	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—CYP4B1—urinary bladder cancer	0.0101	0.0191	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00994	0.0189	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—HPGDS—urinary bladder cancer	0.00916	0.0174	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTT1—urinary bladder cancer	0.00889	0.0169	CbGpPWpGaD
Cyclizine—Urinary retention—Valrubicin—urinary bladder cancer	0.0088	0.0267	CcSEcCtD
Cyclizine—Injection site reaction—Mitomycin—urinary bladder cancer	0.00873	0.0265	CcSEcCtD
Cyclizine—Thrombophlebitis—Mitomycin—urinary bladder cancer	0.00737	0.0223	CcSEcCtD
Cyclizine—HRH1—prostate gland—urinary bladder cancer	0.00673	0.0475	CbGeAlD
Cyclizine—SULT1E1—Biological oxidations—NAT2—urinary bladder cancer	0.00671	0.0127	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—NAT2—urinary bladder cancer	0.00661	0.0125	CbGpPWpGaD
Cyclizine—CYP2C9—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00649	0.0123	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTP1—urinary bladder cancer	0.00616	0.0117	CbGpPWpGaD
Cyclizine—SULT1E1—Phase II conjugation—GSTM1—urinary bladder cancer	0.00566	0.0107	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—HPGDS—urinary bladder cancer	0.00536	0.0102	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00526	0.00999	CbGpPWpGaD
Cyclizine—SULT1E1—Biological oxidations—GSTT1—urinary bladder cancer	0.0052	0.00986	CbGpPWpGaD
Cyclizine—Blister—Fluorouracil—urinary bladder cancer	0.00507	0.0154	CcSEcCtD
Cyclizine—CYP2C9—Arachidonate Epoxygenase / Epoxide Hydrolase—GSTP1—urinary bladder cancer	0.00503	0.00955	CbGpPWpGaD
Cyclizine—HRH1—epithelium—urinary bladder cancer	0.00495	0.0349	CbGeAlD
Cyclizine—Drowsiness—Mitomycin—urinary bladder cancer	0.00491	0.0149	CcSEcCtD
Cyclizine—HRH1—smooth muscle tissue—urinary bladder cancer	0.00477	0.0337	CbGeAlD
Cyclizine—HRH1—urethra—urinary bladder cancer	0.00451	0.0318	CbGeAlD
Cyclizine—Speech disorder—Fluorouracil—urinary bladder cancer	0.00425	0.0129	CcSEcCtD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00397	0.00754	CbGpPWpGaD
Cyclizine—Erythema—Mitomycin—urinary bladder cancer	0.00384	0.0116	CcSEcCtD
Cyclizine—Apnoea—Etoposide—urinary bladder cancer	0.00374	0.0114	CcSEcCtD
Cyclizine—CYP2C9—female reproductive system—urinary bladder cancer	0.00373	0.0263	CbGeAlD
Cyclizine—Injection site reaction—Gemcitabine—urinary bladder cancer	0.00369	0.0112	CcSEcCtD
Cyclizine—HRH1—female reproductive system—urinary bladder cancer	0.00368	0.0259	CbGeAlD
Cyclizine—Vision blurred—Mitomycin—urinary bladder cancer	0.00362	0.011	CcSEcCtD
Cyclizine—SULT1E1—Biological oxidations—GSTP1—urinary bladder cancer	0.0036	0.00684	CbGpPWpGaD
Cyclizine—Pain—Carboplatin—urinary bladder cancer	0.0036	0.0109	CcSEcCtD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.00355	0.00674	CbGpPWpGaD
Cyclizine—HRH1—vagina—urinary bladder cancer	0.00332	0.0235	CbGeAlD
Cyclizine—Hypertension—Mitomycin—urinary bladder cancer	0.00332	0.0101	CcSEcCtD
Cyclizine—SULT1E1—Biological oxidations—GSTM1—urinary bladder cancer	0.00331	0.00628	CbGpPWpGaD
Cyclizine—SULT1E1—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.00327	0.0062	CbGpPWpGaD
Cyclizine—Asthenia—Valrubicin—urinary bladder cancer	0.00326	0.0099	CcSEcCtD
Cyclizine—Pruritus—Valrubicin—urinary bladder cancer	0.00322	0.00976	CcSEcCtD
Cyclizine—Hepatic function abnormal—Gemcitabine—urinary bladder cancer	0.00309	0.00936	CcSEcCtD
Cyclizine—Thrombophlebitis—Fluorouracil—urinary bladder cancer	0.00306	0.00929	CcSEcCtD
Cyclizine—Urinary retention—Thiotepa—urinary bladder cancer	0.00305	0.00925	CcSEcCtD
Cyclizine—Dizziness—Valrubicin—urinary bladder cancer	0.00301	0.00913	CcSEcCtD
Cyclizine—Disorientation—Fluorouracil—urinary bladder cancer	0.00296	0.00899	CcSEcCtD
Cyclizine—CYP2C9—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00292	0.00554	CbGpPWpGaD
Cyclizine—Headache—Valrubicin—urinary bladder cancer	0.00285	0.00864	CcSEcCtD
Cyclizine—Dermatitis bullous—Gemcitabine—urinary bladder cancer	0.00282	0.00856	CcSEcCtD
Cyclizine—Somnolence—Mitomycin—urinary bladder cancer	0.00279	0.00845	CcSEcCtD
Cyclizine—Dermatitis bullous—Fluorouracil—urinary bladder cancer	0.00277	0.00842	CcSEcCtD
Cyclizine—Pain—Mitomycin—urinary bladder cancer	0.00268	0.00813	CcSEcCtD
Cyclizine—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00252	0.00479	CbGpPWpGaD
Cyclizine—CYP2C9—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00249	0.00472	CbGpPWpGaD
Cyclizine—Blister—Epirubicin—urinary bladder cancer	0.00247	0.00749	CcSEcCtD
Cyclizine—Hepatobiliary disease—Thiotepa—urinary bladder cancer	0.00234	0.00709	CcSEcCtD
Cyclizine—Agranulocytosis—Thiotepa—urinary bladder cancer	0.00231	0.007	CcSEcCtD
Cyclizine—Bronchospasm—Gemcitabine—urinary bladder cancer	0.00229	0.00696	CcSEcCtD
Cyclizine—Blister—Doxorubicin—urinary bladder cancer	0.00228	0.00693	CcSEcCtD
Cyclizine—Asthenia—Mitomycin—urinary bladder cancer	0.00225	0.00682	CcSEcCtD
Cyclizine—Apnoea—Methotrexate—urinary bladder cancer	0.00224	0.0068	CcSEcCtD
Cyclizine—Speech disorder—Methotrexate—urinary bladder cancer	0.00221	0.0067	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GSTZ1—urinary bladder cancer	0.00221	0.00419	CbGpPWpGaD
Cyclizine—Connective tissue disorder—Thiotepa—urinary bladder cancer	0.00218	0.00661	CcSEcCtD
Cyclizine—HRH1—lymph node—urinary bladder cancer	0.00215	0.0152	CbGeAlD
Cyclizine—SULT1E1—Metabolism—NAT1—urinary bladder cancer	0.00209	0.00397	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—GSTO2—urinary bladder cancer	0.00209	0.00397	CbGpPWpGaD
Cyclizine—Eye disorder—Thiotepa—urinary bladder cancer	0.00207	0.00629	CcSEcCtD
Cyclizine—Dizziness—Mitomycin—urinary bladder cancer	0.00207	0.00629	CcSEcCtD
Cyclizine—CYP2C9—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00205	0.00388	CbGpPWpGaD
Cyclizine—CYP2C9—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.00204	0.00386	CbGpPWpGaD
Cyclizine—Jaundice cholestatic—Epirubicin—urinary bladder cancer	0.00202	0.00614	CcSEcCtD
Cyclizine—Chills—Thiotepa—urinary bladder cancer	0.00199	0.00604	CcSEcCtD
Cyclizine—Hepatobiliary disease—Gemcitabine—urinary bladder cancer	0.00197	0.00596	CcSEcCtD
Cyclizine—Headache—Mitomycin—urinary bladder cancer	0.00196	0.00596	CcSEcCtD
Cyclizine—Bronchospasm—Etoposide—urinary bladder cancer	0.00196	0.00594	CcSEcCtD
Cyclizine—Mental disorder—Thiotepa—urinary bladder cancer	0.00194	0.0059	CcSEcCtD
Cyclizine—Agranulocytosis—Gemcitabine—urinary bladder cancer	0.00194	0.00588	CcSEcCtD
Cyclizine—Erythema—Thiotepa—urinary bladder cancer	0.00193	0.00586	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—UGT2B7—urinary bladder cancer	0.00191	0.00363	CbGpPWpGaD
Cyclizine—Agranulocytosis—Fluorouracil—urinary bladder cancer	0.00191	0.00579	CcSEcCtD
Cyclizine—Tension—Thiotepa—urinary bladder cancer	0.00189	0.00575	CcSEcCtD
Cyclizine—Dyskinesia—Epirubicin—urinary bladder cancer	0.00189	0.00574	CcSEcCtD
Cyclizine—Nervousness—Thiotepa—urinary bladder cancer	0.00188	0.00569	CcSEcCtD
Cyclizine—Jaundice cholestatic—Doxorubicin—urinary bladder cancer	0.00187	0.00568	CcSEcCtD
Cyclizine—Depressed level of consciousness—Methotrexate—urinary bladder cancer	0.00184	0.00557	CcSEcCtD
Cyclizine—Connective tissue disorder—Gemcitabine—urinary bladder cancer	0.00183	0.00556	CcSEcCtD
Cyclizine—Hepatobiliary disease—Cisplatin—urinary bladder cancer	0.00183	0.00556	CcSEcCtD
Cyclizine—Vision blurred—Thiotepa—urinary bladder cancer	0.00182	0.00552	CcSEcCtD
Cyclizine—Agitation—Thiotepa—urinary bladder cancer	0.00177	0.00538	CcSEcCtD
Cyclizine—Injection site reaction—Epirubicin—urinary bladder cancer	0.00177	0.00536	CcSEcCtD
Cyclizine—Dyskinesia—Doxorubicin—urinary bladder cancer	0.00175	0.00531	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CYP4B1—urinary bladder cancer	0.00172	0.00327	CbGpPWpGaD
Cyclizine—Connective tissue disorder—Cisplatin—urinary bladder cancer	0.00171	0.00518	CcSEcCtD
Cyclizine—Hepatobiliary disease—Etoposide—urinary bladder cancer	0.00168	0.00509	CcSEcCtD
Cyclizine—Chills—Gemcitabine—urinary bladder cancer	0.00167	0.00508	CcSEcCtD
Cyclizine—Convulsion—Thiotepa—urinary bladder cancer	0.00167	0.00508	CcSEcCtD
Cyclizine—Hypertension—Thiotepa—urinary bladder cancer	0.00167	0.00506	CcSEcCtD
Cyclizine—Agranulocytosis—Etoposide—urinary bladder cancer	0.00166	0.00502	CcSEcCtD
Cyclizine—Injection site reaction—Doxorubicin—urinary bladder cancer	0.00164	0.00496	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—SLC19A1—urinary bladder cancer	0.00163	0.00309	CbGpPWpGaD
Cyclizine—Eye disorder—Cisplatin—urinary bladder cancer	0.00163	0.00493	CcSEcCtD
Cyclizine—Erythema—Gemcitabine—urinary bladder cancer	0.00162	0.00493	CcSEcCtD
Cyclizine—Erythema—Fluorouracil—urinary bladder cancer	0.0016	0.00485	CcSEcCtD
Cyclizine—Thrombophlebitis—Methotrexate—urinary bladder cancer	0.00159	0.00483	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PRSS3—urinary bladder cancer	0.00159	0.00301	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.00155	0.00295	CbGpPWpGaD
Cyclizine—Nervous system disorder—Thiotepa—urinary bladder cancer	0.00155	0.00469	CcSEcCtD
Cyclizine—Tachycardia—Thiotepa—urinary bladder cancer	0.00154	0.00467	CcSEcCtD
Cyclizine—Skin disorder—Thiotepa—urinary bladder cancer	0.00153	0.00464	CcSEcCtD
Cyclizine—Erythema—Cisplatin—urinary bladder cancer	0.00151	0.00459	CcSEcCtD
Cyclizine—Vision blurred—Fluorouracil—urinary bladder cancer	0.00151	0.00457	CcSEcCtD
Cyclizine—Thrombophlebitis—Epirubicin—urinary bladder cancer	0.00149	0.00452	CcSEcCtD
Cyclizine—Eye disorder—Etoposide—urinary bladder cancer	0.00149	0.00452	CcSEcCtD
Cyclizine—Hepatic function abnormal—Epirubicin—urinary bladder cancer	0.00148	0.00448	CcSEcCtD
Cyclizine—Muscle spasms—Cisplatin—urinary bladder cancer	0.00146	0.00442	CcSEcCtD
Cyclizine—Benzphetamine—POR—urinary bladder cancer	0.00145	1	CrCbGaD
Cyclizine—Chills—Etoposide—urinary bladder cancer	0.00143	0.00434	CcSEcCtD
Cyclizine—Vision blurred—Cisplatin—urinary bladder cancer	0.00143	0.00433	CcSEcCtD
Cyclizine—Tremor—Cisplatin—urinary bladder cancer	0.00142	0.0043	CcSEcCtD
Cyclizine—Paraesthesia—Thiotepa—urinary bladder cancer	0.00142	0.00429	CcSEcCtD
Cyclizine—Hypertension—Gemcitabine—urinary bladder cancer	0.0014	0.00425	CcSEcCtD
Cyclizine—Somnolence—Thiotepa—urinary bladder cancer	0.0014	0.00425	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTZ1—urinary bladder cancer	0.00139	0.00264	CbGpPWpGaD
Cyclizine—Convulsion—Fluorouracil—urinary bladder cancer	0.00138	0.0042	CcSEcCtD
Cyclizine—Thrombophlebitis—Doxorubicin—urinary bladder cancer	0.00138	0.00419	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.00137	0.0026	CbGpPWpGaD
Cyclizine—Hepatic function abnormal—Doxorubicin—urinary bladder cancer	0.00137	0.00415	CcSEcCtD
Cyclizine—Dermatitis bullous—Epirubicin—urinary bladder cancer	0.00135	0.0041	CcSEcCtD
Cyclizine—Constipation—Thiotepa—urinary bladder cancer	0.00135	0.00409	CcSEcCtD
Cyclizine—Pain—Thiotepa—urinary bladder cancer	0.00135	0.00409	CcSEcCtD
Cyclizine—Muscle spasms—Etoposide—urinary bladder cancer	0.00133	0.00405	CcSEcCtD
Cyclizine—Anaphylactic shock—Gemcitabine—urinary bladder cancer	0.00133	0.00402	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTO2—urinary bladder cancer	0.00132	0.0025	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—NAT1—urinary bladder cancer	0.00132	0.0025	CbGpPWpGaD
Cyclizine—Convulsion—Cisplatin—urinary bladder cancer	0.00131	0.00398	CcSEcCtD
Cyclizine—Anaphylactic shock—Fluorouracil—urinary bladder cancer	0.0013	0.00395	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.0013	0.00247	CbGpPWpGaD
Cyclizine—Nervous system disorder—Gemcitabine—urinary bladder cancer	0.0013	0.00394	CcSEcCtD
Cyclizine—Skin disorder—Gemcitabine—urinary bladder cancer	0.00129	0.00391	CcSEcCtD
Cyclizine—Nervous system disorder—Fluorouracil—urinary bladder cancer	0.00128	0.00388	CcSEcCtD
Cyclizine—Tachycardia—Fluorouracil—urinary bladder cancer	0.00127	0.00386	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—TYMP—urinary bladder cancer	0.00127	0.00241	CbGpPWpGaD
Cyclizine—Urticaria—Thiotepa—urinary bladder cancer	0.00125	0.0038	CcSEcCtD
Cyclizine—Dermatitis bullous—Doxorubicin—urinary bladder cancer	0.00125	0.00379	CcSEcCtD
Cyclizine—Hypotension—Gemcitabine—urinary bladder cancer	0.00124	0.00376	CcSEcCtD
Cyclizine—Anaphylactic shock—Cisplatin—urinary bladder cancer	0.00124	0.00375	CcSEcCtD
Cyclizine—Hypotension—Fluorouracil—urinary bladder cancer	0.00122	0.00369	CcSEcCtD
Cyclizine—Nervous system disorder—Cisplatin—urinary bladder cancer	0.00121	0.00368	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—UGT2B7—urinary bladder cancer	0.00121	0.00229	CbGpPWpGaD
Cyclizine—Tachycardia—Cisplatin—urinary bladder cancer	0.00121	0.00366	CcSEcCtD
Cyclizine—Convulsion—Etoposide—urinary bladder cancer	0.0012	0.00365	CcSEcCtD
Cyclizine—Skin disorder—Cisplatin—urinary bladder cancer	0.0012	0.00364	CcSEcCtD
Cyclizine—Insomnia—Gemcitabine—urinary bladder cancer	0.0012	0.00364	CcSEcCtD
Cyclizine—Hypertension—Etoposide—urinary bladder cancer	0.0012	0.00363	CcSEcCtD
Cyclizine—Paraesthesia—Gemcitabine—urinary bladder cancer	0.00119	0.00361	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.00119	0.00226	CbGpPWpGaD
Cyclizine—Insomnia—Fluorouracil—urinary bladder cancer	0.00118	0.00358	CcSEcCtD
Cyclizine—Somnolence—Gemcitabine—urinary bladder cancer	0.00118	0.00358	CcSEcCtD
Cyclizine—Paraesthesia—Fluorouracil—urinary bladder cancer	0.00117	0.00355	CcSEcCtD
Cyclizine—Hypersensitivity—Thiotepa—urinary bladder cancer	0.00116	0.00352	CcSEcCtD
Cyclizine—Somnolence—Fluorouracil—urinary bladder cancer	0.00116	0.00352	CcSEcCtD
Cyclizine—Hypotension—Cisplatin—urinary bladder cancer	0.00115	0.0035	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—NAT2—urinary bladder cancer	0.00115	0.00218	CbGpPWpGaD
Cyclizine—Constipation—Gemcitabine—urinary bladder cancer	0.00113	0.00344	CcSEcCtD
Cyclizine—Pain—Gemcitabine—urinary bladder cancer	0.00113	0.00344	CcSEcCtD
Cyclizine—Anaphylactic shock—Etoposide—urinary bladder cancer	0.00113	0.00343	CcSEcCtD
Cyclizine—Asthenia—Thiotepa—urinary bladder cancer	0.00113	0.00343	CcSEcCtD
Cyclizine—Pruritus—Thiotepa—urinary bladder cancer	0.00111	0.00338	CcSEcCtD
Cyclizine—Pain—Fluorouracil—urinary bladder cancer	0.00111	0.00338	CcSEcCtD
Cyclizine—Paraesthesia—Cisplatin—urinary bladder cancer	0.00111	0.00337	CcSEcCtD
Cyclizine—Tachycardia—Etoposide—urinary bladder cancer	0.0011	0.00335	CcSEcCtD
Cyclizine—Skin disorder—Etoposide—urinary bladder cancer	0.0011	0.00334	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—CYP4B1—urinary bladder cancer	0.00109	0.00206	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.00107	0.00203	CbGpPWpGaD
Cyclizine—Drowsiness—Methotrexate—urinary bladder cancer	0.00106	0.00323	CcSEcCtD
Cyclizine—Hypotension—Etoposide—urinary bladder cancer	0.00106	0.00321	CcSEcCtD
Cyclizine—Pain—Cisplatin—urinary bladder cancer	0.00106	0.00321	CcSEcCtD
Cyclizine—Dizziness—Thiotepa—urinary bladder cancer	0.00104	0.00316	CcSEcCtD
Cyclizine—Urticaria—Fluorouracil—urinary bladder cancer	0.00104	0.00314	CcSEcCtD
Cyclizine—Paraesthesia—Etoposide—urinary bladder cancer	0.00102	0.00308	CcSEcCtD
Cyclizine—Somnolence—Etoposide—urinary bladder cancer	0.00101	0.00305	CcSEcCtD
Cyclizine—Hepatobiliary disease—Methotrexate—urinary bladder cancer	0.00101	0.00305	CcSEcCtD
Cyclizine—Drowsiness—Epirubicin—urinary bladder cancer	0.000995	0.00302	CcSEcCtD
Cyclizine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000992	0.00301	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—RRM2—urinary bladder cancer	0.00099	0.00188	CbGpPWpGaD
Cyclizine—Headache—Thiotepa—urinary bladder cancer	0.000987	0.003	CcSEcCtD
Cyclizine—Pain—Etoposide—urinary bladder cancer	0.000968	0.00294	CcSEcCtD
Cyclizine—Constipation—Etoposide—urinary bladder cancer	0.000968	0.00294	CcSEcCtD
Cyclizine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.00096	0.00291	CcSEcCtD
Cyclizine—Hepatitis—Methotrexate—urinary bladder cancer	0.000954	0.0029	CcSEcCtD
Cyclizine—Asthenia—Gemcitabine—urinary bladder cancer	0.000951	0.00289	CcSEcCtD
Cyclizine—Hepatobiliary disease—Epirubicin—urinary bladder cancer	0.000941	0.00285	CcSEcCtD
Cyclizine—Pruritus—Gemcitabine—urinary bladder cancer	0.000938	0.00285	CcSEcCtD
Cyclizine—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000936	0.00178	CbGpPWpGaD
Cyclizine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000928	0.00282	CcSEcCtD
Cyclizine—Pruritus—Fluorouracil—urinary bladder cancer	0.000922	0.0028	CcSEcCtD
Cyclizine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000921	0.00279	CcSEcCtD
Cyclizine—CYP2C9—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000919	0.00174	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—ENO2—urinary bladder cancer	0.000917	0.00174	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—HPGDS—urinary bladder cancer	0.000917	0.00174	CbGpPWpGaD
Cyclizine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.00091	0.00276	CcSEcCtD
Cyclizine—Urticaria—Etoposide—urinary bladder cancer	0.000899	0.00273	CcSEcCtD
Cyclizine—Hepatitis—Epirubicin—urinary bladder cancer	0.000893	0.00271	CcSEcCtD
Cyclizine—Eye disorder—Methotrexate—urinary bladder cancer	0.000892	0.00271	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GSTT1—urinary bladder cancer	0.000889	0.00169	CbGpPWpGaD
Cyclizine—Asthenia—Cisplatin—urinary bladder cancer	0.000887	0.00269	CcSEcCtD
Cyclizine—Connective tissue disorder—Epirubicin—urinary bladder cancer	0.000878	0.00266	CcSEcCtD
Cyclizine—Hepatobiliary disease—Doxorubicin—urinary bladder cancer	0.000871	0.00264	CcSEcCtD
Cyclizine—Dizziness—Fluorouracil—urinary bladder cancer	0.000862	0.00261	CcSEcCtD
Cyclizine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000859	0.00261	CcSEcCtD
Cyclizine—Chills—Methotrexate—urinary bladder cancer	0.000856	0.0026	CcSEcCtD
Cyclizine—Mental disorder—Methotrexate—urinary bladder cancer	0.000836	0.00254	CcSEcCtD
Cyclizine—Eye disorder—Epirubicin—urinary bladder cancer	0.000835	0.00253	CcSEcCtD
Cyclizine—Hypersensitivity—Etoposide—urinary bladder cancer	0.000834	0.00253	CcSEcCtD
Cyclizine—Erythema—Methotrexate—urinary bladder cancer	0.000831	0.00252	CcSEcCtD
Cyclizine—Headache—Gemcitabine—urinary bladder cancer	0.00083	0.00252	CcSEcCtD
Cyclizine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000826	0.00251	CcSEcCtD
Cyclizine—Headache—Fluorouracil—urinary bladder cancer	0.000817	0.00248	CcSEcCtD
Cyclizine—Asthenia—Etoposide—urinary bladder cancer	0.000812	0.00246	CcSEcCtD
Cyclizine—Connective tissue disorder—Doxorubicin—urinary bladder cancer	0.000812	0.00246	CcSEcCtD
Cyclizine—Chills—Epirubicin—urinary bladder cancer	0.000801	0.00243	CcSEcCtD
Cyclizine—Pruritus—Etoposide—urinary bladder cancer	0.000801	0.00243	CcSEcCtD
Cyclizine—Vision blurred—Methotrexate—urinary bladder cancer	0.000783	0.00238	CcSEcCtD
Cyclizine—Mental disorder—Epirubicin—urinary bladder cancer	0.000782	0.00237	CcSEcCtD
Cyclizine—Erythema—Epirubicin—urinary bladder cancer	0.000778	0.00236	CcSEcCtD
Cyclizine—Eye disorder—Doxorubicin—urinary bladder cancer	0.000772	0.00234	CcSEcCtD
Cyclizine—Tension—Epirubicin—urinary bladder cancer	0.000763	0.00231	CcSEcCtD
Cyclizine—Nervousness—Epirubicin—urinary bladder cancer	0.000755	0.00229	CcSEcCtD
Cyclizine—Dizziness—Etoposide—urinary bladder cancer	0.000749	0.00227	CcSEcCtD
Cyclizine—Muscle spasms—Epirubicin—urinary bladder cancer	0.000748	0.00227	CcSEcCtD
Cyclizine—Chills—Doxorubicin—urinary bladder cancer	0.000742	0.00225	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—NQO1—urinary bladder cancer	0.000739	0.0014	CbGpPWpGaD
Cyclizine—Vision blurred—Epirubicin—urinary bladder cancer	0.000733	0.00222	CcSEcCtD
Cyclizine—Mental disorder—Doxorubicin—urinary bladder cancer	0.000724	0.0022	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—NAT2—urinary bladder cancer	0.000723	0.00137	CbGpPWpGaD
Cyclizine—Convulsion—Methotrexate—urinary bladder cancer	0.00072	0.00218	CcSEcCtD
Cyclizine—Erythema—Doxorubicin—urinary bladder cancer	0.000719	0.00218	CcSEcCtD
Cyclizine—HRH1—IL-4 Signaling Pathway—EP300—urinary bladder cancer	0.000718	0.00136	CbGpPWpGaD
Cyclizine—Agitation—Epirubicin—urinary bladder cancer	0.000715	0.00217	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000713	0.00135	CbGpPWpGaD
Cyclizine—Headache—Etoposide—urinary bladder cancer	0.000709	0.00215	CcSEcCtD
Cyclizine—Tension—Doxorubicin—urinary bladder cancer	0.000706	0.00214	CcSEcCtD
Cyclizine—Nervousness—Doxorubicin—urinary bladder cancer	0.000699	0.00212	CcSEcCtD
Cyclizine—Muscle spasms—Doxorubicin—urinary bladder cancer	0.000692	0.0021	CcSEcCtD
Cyclizine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000678	0.00206	CcSEcCtD
Cyclizine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000678	0.00206	CcSEcCtD
Cyclizine—Convulsion—Epirubicin—urinary bladder cancer	0.000674	0.00204	CcSEcCtD
Cyclizine—Hypertension—Epirubicin—urinary bladder cancer	0.000671	0.00204	CcSEcCtD
Cyclizine—Nervous system disorder—Methotrexate—urinary bladder cancer	0.000665	0.00202	CcSEcCtD
Cyclizine—Agitation—Doxorubicin—urinary bladder cancer	0.000661	0.00201	CcSEcCtD
Cyclizine—Skin disorder—Methotrexate—urinary bladder cancer	0.000659	0.002	CcSEcCtD
Cyclizine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000635	0.00193	CcSEcCtD
Cyclizine—Hypotension—Methotrexate—urinary bladder cancer	0.000634	0.00192	CcSEcCtD
Cyclizine—Convulsion—Doxorubicin—urinary bladder cancer	0.000623	0.00189	CcSEcCtD
Cyclizine—Nervous system disorder—Epirubicin—urinary bladder cancer	0.000622	0.00189	CcSEcCtD
Cyclizine—Hypertension—Doxorubicin—urinary bladder cancer	0.000621	0.00188	CcSEcCtD
Cyclizine—Tachycardia—Epirubicin—urinary bladder cancer	0.000619	0.00188	CcSEcCtD
Cyclizine—Skin disorder—Epirubicin—urinary bladder cancer	0.000616	0.00187	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GSTP1—urinary bladder cancer	0.000616	0.00117	CbGpPWpGaD
Cyclizine—Insomnia—Methotrexate—urinary bladder cancer	0.000613	0.00186	CcSEcCtD
Cyclizine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000609	0.00185	CcSEcCtD
Cyclizine—Somnolence—Methotrexate—urinary bladder cancer	0.000603	0.00183	CcSEcCtD
Cyclizine—Hypotension—Epirubicin—urinary bladder cancer	0.000593	0.0018	CcSEcCtD
Cyclizine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000587	0.00178	CcSEcCtD
Cyclizine—Pain—Methotrexate—urinary bladder cancer	0.00058	0.00176	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—HPGDS—urinary bladder cancer	0.000578	0.0011	CbGpPWpGaD
Cyclizine—Nervous system disorder—Doxorubicin—urinary bladder cancer	0.000576	0.00175	CcSEcCtD
Cyclizine—Insomnia—Epirubicin—urinary bladder cancer	0.000574	0.00174	CcSEcCtD
Cyclizine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000573	0.00174	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—TYMS—urinary bladder cancer	0.000573	0.00109	CbGpPWpGaD
Cyclizine—Skin disorder—Doxorubicin—urinary bladder cancer	0.00057	0.00173	CcSEcCtD
Cyclizine—Paraesthesia—Epirubicin—urinary bladder cancer	0.00057	0.00173	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GSTM1—urinary bladder cancer	0.000566	0.00107	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—NCOR1—urinary bladder cancer	0.000566	0.00107	CbGpPWpGaD
Cyclizine—Somnolence—Epirubicin—urinary bladder cancer	0.000564	0.00171	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTT1—urinary bladder cancer	0.000561	0.00106	CbGpPWpGaD
Cyclizine—Hypotension—Doxorubicin—urinary bladder cancer	0.000549	0.00166	CcSEcCtD
Cyclizine—Pain—Epirubicin—urinary bladder cancer	0.000543	0.00165	CcSEcCtD
Cyclizine—Constipation—Epirubicin—urinary bladder cancer	0.000543	0.00165	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—GPX1—urinary bladder cancer	0.000542	0.00103	CbGpPWpGaD
Cyclizine—CYP2C9—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000541	0.00103	CbGpPWpGaD
Cyclizine—Urticaria—Methotrexate—urinary bladder cancer	0.000539	0.00163	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—ERCC2—urinary bladder cancer	0.000533	0.00101	CbGpPWpGaD
Cyclizine—Insomnia—Doxorubicin—urinary bladder cancer	0.000531	0.00161	CcSEcCtD
Cyclizine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000527	0.0016	CcSEcCtD
Cyclizine—Somnolence—Doxorubicin—urinary bladder cancer	0.000522	0.00158	CcSEcCtD
Cyclizine—Urticaria—Epirubicin—urinary bladder cancer	0.000504	0.00153	CcSEcCtD
Cyclizine—Pain—Doxorubicin—urinary bladder cancer	0.000502	0.00152	CcSEcCtD
Cyclizine—Constipation—Doxorubicin—urinary bladder cancer	0.000502	0.00152	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—MTHFR—urinary bladder cancer	0.000501	0.000949	CbGpPWpGaD
Cyclizine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.0005	0.00152	CcSEcCtD
Cyclizine—Asthenia—Methotrexate—urinary bladder cancer	0.000486	0.00148	CcSEcCtD
Cyclizine—Pruritus—Methotrexate—urinary bladder cancer	0.00048	0.00146	CcSEcCtD
Cyclizine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000468	0.00142	CcSEcCtD
Cyclizine—Urticaria—Doxorubicin—urinary bladder cancer	0.000466	0.00142	CcSEcCtD
Cyclizine—Asthenia—Epirubicin—urinary bladder cancer	0.000455	0.00138	CcSEcCtD
Cyclizine—Pruritus—Epirubicin—urinary bladder cancer	0.000449	0.00136	CcSEcCtD
Cyclizine—Dizziness—Methotrexate—urinary bladder cancer	0.000448	0.00136	CcSEcCtD
Cyclizine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000433	0.00131	CcSEcCtD
Cyclizine—Headache—Methotrexate—urinary bladder cancer	0.000425	0.00129	CcSEcCtD
Cyclizine—Asthenia—Doxorubicin—urinary bladder cancer	0.000421	0.00128	CcSEcCtD
Cyclizine—Dizziness—Epirubicin—urinary bladder cancer	0.00042	0.00127	CcSEcCtD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000417	0.000791	CbGpPWpGaD
Cyclizine—Pruritus—Doxorubicin—urinary bladder cancer	0.000415	0.00126	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—PPARG—urinary bladder cancer	0.000406	0.00077	CbGpPWpGaD
Cyclizine—Headache—Epirubicin—urinary bladder cancer	0.000398	0.00121	CcSEcCtD
Cyclizine—SULT1E1—Metabolism—CREBBP—urinary bladder cancer	0.00039	0.00074	CbGpPWpGaD
Cyclizine—CYP2C9—Biological oxidations—GSTP1—urinary bladder cancer	0.000389	0.000737	CbGpPWpGaD
Cyclizine—Dizziness—Doxorubicin—urinary bladder cancer	0.000388	0.00118	CcSEcCtD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000383	0.000727	CbGpPWpGaD
Cyclizine—Headache—Doxorubicin—urinary bladder cancer	0.000368	0.00112	CcSEcCtD
Cyclizine—CYP2C9—Biological oxidations—GSTM1—urinary bladder cancer	0.000357	0.000677	CbGpPWpGaD
Cyclizine—CYP2C9—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000352	0.000668	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTGS2—urinary bladder cancer	0.000319	0.000606	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—PTEN—urinary bladder cancer	0.000278	0.000528	CbGpPWpGaD
Cyclizine—SULT1E1—Metabolism—EP300—urinary bladder cancer	0.000266	0.000504	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTZ1—urinary bladder cancer	0.000238	0.000451	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HDAC4—urinary bladder cancer	0.000232	0.000439	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTO2—urinary bladder cancer	0.000226	0.000428	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAT1—urinary bladder cancer	0.000226	0.000428	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	0.000222	0.000421	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—UGT2B7—urinary bladder cancer	0.000206	0.000391	CbGpPWpGaD
Cyclizine—HRH1—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000205	0.000389	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.000203	0.000384	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—GLI1—urinary bladder cancer	0.000194	0.000368	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	0.000191	0.000363	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CYP4B1—urinary bladder cancer	0.000186	0.000352	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—SLC19A1—urinary bladder cancer	0.000175	0.000333	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PRSS3—urinary bladder cancer	0.000171	0.000324	CbGpPWpGaD
Cyclizine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	0.000163	0.000309	CbGpPWpGaD
Cyclizine—HRH1—GPCR ligand binding—CXCL8—urinary bladder cancer	0.000156	0.000297	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	0.000137	0.00026	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TYMP—urinary bladder cancer	0.000137	0.000259	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RBX1—urinary bladder cancer	0.000133	0.000252	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	0.000131	0.000249	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TSC1—urinary bladder cancer	0.000125	0.000237	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NAT2—urinary bladder cancer	0.000124	0.000235	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—JAG1—urinary bladder cancer	0.000119	0.000226	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—RRM2—urinary bladder cancer	0.000107	0.000202	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—RHOA—urinary bladder cancer	0.000101	0.000191	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ENO2—urinary bladder cancer	9.88e-05	0.000187	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—HPGDS—urinary bladder cancer	9.88e-05	0.000187	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	9.83e-05	0.000186	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—S100B—urinary bladder cancer	9.64e-05	0.000183	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTT1—urinary bladder cancer	9.59e-05	0.000182	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	9.44e-05	0.000179	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—RHOA—urinary bladder cancer	9.14e-05	0.000173	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—CXCL8—urinary bladder cancer	8.84e-05	0.000168	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—NCOR1—urinary bladder cancer	8.67e-05	0.000164	CbGpPWpGaD
Cyclizine—HRH1—GPCR downstream signaling—IL2—urinary bladder cancer	8.44e-05	0.00016	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—CXCL8—urinary bladder cancer	8.02e-05	0.000152	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NQO1—urinary bladder cancer	7.97e-05	0.000151	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	7.73e-05	0.000147	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—IL2—urinary bladder cancer	7.67e-05	0.000145	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TERT—urinary bladder cancer	7.64e-05	0.000145	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—FGFR3—urinary bladder cancer	7.01e-05	0.000133	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ESR1—urinary bladder cancer	6.81e-05	0.000129	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	6.74e-05	0.000128	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTP1—urinary bladder cancer	6.65e-05	0.000126	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	6.43e-05	0.000122	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—TYMS—urinary bladder cancer	6.18e-05	0.000117	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GSTM1—urinary bladder cancer	6.11e-05	0.000116	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—NCOR1—urinary bladder cancer	6.11e-05	0.000116	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CREBBP—urinary bladder cancer	5.97e-05	0.000113	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IGF1—urinary bladder cancer	5.89e-05	0.000112	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—EGFR—urinary bladder cancer	5.86e-05	0.000111	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—GPX1—urinary bladder cancer	5.85e-05	0.000111	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—ERCC2—urinary bladder cancer	5.74e-05	0.000109	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—KRAS—urinary bladder cancer	5.54e-05	0.000105	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—RHOA—urinary bladder cancer	5.4e-05	0.000102	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—MTHFR—urinary bladder cancer	5.4e-05	0.000102	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—ERBB2—urinary bladder cancer	5e-05	9.48e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CXCL8—urinary bladder cancer	4.74e-05	8.99e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling by GPCR—HRAS—urinary bladder cancer	4.71e-05	8.93e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—IL2—urinary bladder cancer	4.53e-05	8.59e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CCND1—urinary bladder cancer	4.42e-05	8.38e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PPARG—urinary bladder cancer	4.38e-05	8.3e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MMP9—urinary bladder cancer	4.29e-05	8.13e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—CDKN1A—urinary bladder cancer	4.27e-05	8.1e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—PTEN—urinary bladder cancer	4.26e-05	8.08e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—CREBBP—urinary bladder cancer	4.2e-05	7.97e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EP300—urinary bladder cancer	4.06e-05	7.71e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—SRC—urinary bladder cancer	3.95e-05	7.5e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—MYC—urinary bladder cancer	3.54e-05	6.72e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—EGFR—urinary bladder cancer	3.46e-05	6.57e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTGS2—urinary bladder cancer	3.44e-05	6.53e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—KRAS—urinary bladder cancer	3.27e-05	6.21e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—PTEN—urinary bladder cancer	3e-05	5.69e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—TP53—urinary bladder cancer	2.91e-05	5.52e-05	CbGpPWpGaD
Cyclizine—CYP2C9—Metabolism—EP300—urinary bladder cancer	2.86e-05	5.43e-05	CbGpPWpGaD
Cyclizine—HRH1—Signaling Pathways—HRAS—urinary bladder cancer	2.78e-05	5.28e-05	CbGpPWpGaD
